Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND: Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It was hypothesized that a poor Eastern Cooperative Oncology Group (ECOG) PS (≥2 vs 0-1) would correlate with shorter overall survival (OS) in patients receiving ICIs. METHODS: In this retrospective cohort study, clinicopathologic, treatment, and outcome data were collected for patients with aUC who were treated with ICIs at 18 institutions (2013-2019). The overall response rate (ORR) and OS were compared for patients with an ECOG PS of 0 to 1 and patients with an ECOG PS ≥ 2 at ICI initiation. The association between a new ICI in the last 30 and 90 days of life (DOL) and death location was also tested. RESULTS: Of the 519 patients treated with ICIs, 395 and 384 were included in OS and ORR analyses, respectively, with 26% and 24% having a PS ≥ 2. OS was higher in those with a PS of 0 to 1 than those with a PS ≥ 2 who were treated in the first line (median, 15.2 vs 7.2 months; hazard ratio [HR], 0.62; P = .01) but not in subsequent lines (median, 9.8 vs 8.2 months; HR, 0.78; P = .27). ORRs were similar for patients with a PS of 0 to 1 and patients with a PS ≥ 2 in both lines. Of the 288 patients who died, 10% and 32% started ICIs in the last 30 and 90 DOL, respectively. ICI initiation in the last 30 DOL was associated with increased odds of death in a hospital (odds ratio, 2.89; P = .04). CONCLUSIONS: Despite comparable ORRs, ICIs may not overcome the negative prognostic role of a poor PS, particularly in the first-line setting, and the initiation of ICIs in the last 30 DOL was associated with hospital death location.

Full Text

Duke Authors

Cited Authors

  • Khaki, AR; Li, A; Diamantopoulos, LN; Bilen, MA; Santos, V; Esther, J; Morales-Barrera, R; Devitt, M; Nelson, A; Hoimes, CJ; Shreck, E; Assi, H; Gartrell, BA; Sankin, A; Rodriguez-Vida, A; Lythgoe, M; Pinato, DJ; Drakaki, A; Joshi, M; Isaacsson Velho, P; Hahn, N; Liu, S; Alonso Buznego, L; Duran, I; Moses, M; Jain, J; Murgic, J; Baratam, P; Barata, P; Tripathi, A; Zakharia, Y; Galsky, MD; Sonpavde, G; Yu, EY; Shankaran, V; Lyman, GH; Grivas, P

Published Date

  • March 15, 2020

Published In

Volume / Issue

  • 126 / 6

Start / End Page

  • 1208 - 1216

PubMed ID

  • 31829450

Pubmed Central ID

  • 31829450

Electronic International Standard Serial Number (EISSN)

  • 1097-0142

Digital Object Identifier (DOI)

  • 10.1002/cncr.32645

Language

  • eng

Conference Location

  • United States